Pharmather Holdings Ltd · CSE:PHRM
Pharmather — Investor Presentation (October 2020)
22 slides from Pharmather's investor presentation, October 2020
Slide 1: Fighting Disorders of the Brain and Nervous System with Psychedelic Pharmaceuticals
Psychedelics Life Sciences Company Fighting Disorders of the Brain and Nervous System with Psychedelic Pharmaceuticals Corporate Presentation Pharmather Inc. 8 2 R i c h m o n d S t r e e t E a s t , To r o n t o , O N , M 5 C 1 P 1 C a n a d a October 2020 Te l : 1 - 8 8 8 - 8 4 6 - 3 1 7 1 | i n f
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation of Newscope Capital Corporation (dbd Pharmather Inc.) (“Pharmather”) contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of Pharmather, the anticipated date
Slide 3: Key Takeaways
Key Takeaways 1 Psychedelics life sciences company 5 Broad intellectual property portfolio 2 Target large unmet medical needs with psychedelic pharmaceuticals 6 Experienced team and world-class partnerships 3 Unique AI discovery, development and delivery platforms 7 Undervalued compared to peers 4 R
Slide 4: Current Landscape: Psychedelic Pharmaceuticals Renaissance
Current Landscape Psychedelic Pharmaceuticals Renaissance ü FDA approved Ketamine (Spravato®) for treatment-resistant depression (TRD) and major depressive disorder ü FDA designated both MDMA-assisted psychotherapy for PTSD and psilocybin for TRD as ‘breakthrough therapies’ Popular Psychedelics Worl
Slide 5: About Us
About Us Developing Psychedelic Pharmaceuticals Mission Focus Strategy Discover and develop new Develop psychedelics for FDA Reduce cost, time, uses of psychedelic approval by repurposing with development risk and leverage pharmaceuticals for disorders AI and combining with FDA FDA incentives such a
Slide 6: Our Product Pipeline
Our Product Pipeline Psychedelic Focused FDA Clinical Developments Product Indication Preclinical Phase I / II Phase III Ketamine (PT-001) Parkinson’s Disease 505(b)(2) Ketamine (PT-002) Depression 505(b)(2) Psilocybin Traumatic Brain Injury (Concussion) (PT-004) Psilocybin Stroke (PT-005) Undisclos
Slide 7: Catalysts
Catalysts Over Next 4 Months Over Next 12 Months ü FDA IND acceptance – Ketamine for Parkinson’s Disease ü FDA Phase 2 study results – Ketamine for Parkinson’s Disease ü FDA IND acceptance – Ketamine for Depression ü FDA Phase 2 study interim results – Ketamine for Depression ü FDA Orphan designatio
Slide 8: Our Market Opportunity
Our Market Opportunity $100 Billion Market Potential Initial Targets Future Targets Alzheimer’s Bipolar Disorder Schizophrenia Disease Autism Substance Seizures Spectrum Abuse Disorders Anorexia & Huntington’s Bulimia Neuropathy Disease Disorders USA prevalence statistics …..and more! 8
Slide 9: Our Proprietary Platforms
Our Proprietary Platforms Discovery Development Delivery panaceAI™ Artificial Intelligence for new R&D in combining psychedelics Novel microneedle delivery uses of psychedelics and with FDA approved drugs system for psychedelics combinations with FDA drugs 9
Slide 10: Discovery: panaceAI repurposing with AI
Discovery: panaceAI™ repurposing with AI De-risking Pathway to Clinical Trials and Partnerships Psychedelic compounds Value-Inflection AI Predictions Research AI Learning Preclinical Clinical Trials Predict Targets Generate Data Refine Results Validate Results Commercialize Identify target(s) bindin
Slide 11: Development: Novel Combinations
Development: Novel Combinations PSYCHEDELIC COMPOUND APPROVED DRUG NOVEL DRUG COMBINATION panaceAI™ ü FDA 505(b)(2) pathway ü Enhance efficacy (synergistic) ü Hit identification of +3,500 FDA ü Known safety profile ü Improve safety approved drugs via deep neuro ü Known efficacy profile ü Eliminate /
Slide 12: Delivery: Microneedle patch
Delivery: Microneedle patch Delivering Psychedelic Pharmaceuticals ü Biocompatible and biodegradable gelatin methacryloyl (GelMA) composite ü Penetrates skin and mucosa, flexible drug load capacity and combinations, controlled-release ü Improved delivery over oral, injection, topical and nasal deliv
Slide 13: Ketamine: FDA Approved Psychedelic
Ketamine: FDA Approved Psychedelic Massive Potential ALSO Significant Limitations Cognitive impairment Potent anesthetic Hallucinations, Blurred Vision, Memory Loss, Nausea, Dizziness Powerful pain reliver Abuse liability, Tolerance Effective in treatment Increased Blood Pressure, resistant depressi
Slide 14: Our Solution to Ketamine
Our Solution to Ketamine Combining Ketamine with FDA Approved Drug Cognitive impairment Effective in depression models Hallucinations, Blurred Vision, Memory Loss, Nausea, Dizziness Enhances efficacy of Ketamine Abuse liability, Tolerance Reduces psychotomimetic side Increased Blood Pressure, effect
Slide 15: Depression Overview
Depression Overview Prevalence Unmet Need Treatments +260M 63% of major depressive disorder patients have Oral anti-depressants and atypical antipsychotics Patients globally inadequate response to have significant side effects +17M initial therapy and second i.e. Anxiety, sexual dysfunction, insomni
Slide 16: Parkinson's Disease Overview
Parkinson’s Disease Overview Prevalence Unmet Need Treatments 10M No cure and management of Gold standard for motor the disease consists of the symptoms is levodopa + Patients globally use of treatments that carbidopa where benefits 1M attempt to control motor wear off more quickly and symptoms prim
Slide 17: Our Solution: Ketamine
Our Solution: Ketamine Human Clinical Evidence | Exclusive License from U of Arizona ü Robust data of tolerability, safety and long-term reduction of abnormal involuntary movements ü Reduces L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression in Parkinson’s patients ü ‘Chemical d
Slide 18: Intellectual Property
Intellectual Property Robust IP Portfolio of Patent Coverage into 2040 panaceAI™ Microneedle Delivery System Serial No. PCT/US19/58333 Serial No. 63/011,471 Biodegradable gelatine methacryloyl microneedles for Method of Identifying New Medical Indications for transdermal drug delivery Pharmaceutical
Slide 19: Key Relationships
Key Relationships panaceAI™ Research Exclusive License for Ketamine in and Development Motor Disorders (PD, Pain, Depression) Psilocybin and Ketamine Drug Development, Research and Development Clinical and Regulatory Affairs 19
Slide 20: Team: AI, Drug Development and Capital Markets Experience
Team AI, Drug Development and Capital Markets Experience Management and Advisors Board of Directors Fabio Chianelli Fabio Chianelli, Chairman & CEO Chairman & CEO • Past Founder, CEO, President of Revive Therapeutics Ltd. • Past Founder, CEO, President of Revive Therapeutics Ltd. Dr. Bev Incledon, D
Slide 21: Peer Comparison Market Caps
Peer Comparison Market Caps as of October 9, 2020 $1.20 Billion Phase 2b | Psilocybin | TRD $385 Million Phase 2 | LSD / Ibogaine | CNS $13 Million *Phase 2 | Ketamine / Psilocybin| PD, TRD, TBI * Initiate < 6 months 21
Slide 22: Financial Snapshot
Financial Snapshot 65,376,000 I/O Common Shares $0.195 $13M 1,802,200 Warrants Share Price Market Cap 4,875,000 Stock Options Newscope Capital Corporation Figures as of October 9, 2020 (d/b/a Pharmather) 22
Pharmather Holdings — Investor Presentation (October 2020) on 6ix